Evidence map›Paper›PMID 41605828›Full record

ReviewRambam Maimonides medical journal2026

Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review.

Randy Adiwinata, Caroline Tanadi, Fegita Beatrix Pajala, Kevin Tandarto, Maureen Miracle Stella, Jeffry Beta Tenggara, Ralph Girson Gunarsa, Paulus Simadibrata, Lianda Siregar, Saut Horas Hatoguan Nababan and 4 more

Abstract readReview
In one paragraph

Review in Rambam Maimonides medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Randy AdiwinataGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.
Caroline TanadiSchool of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Fegita Beatrix PajalaSchool of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Kevin TandartoSchool of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Maureen Miracle StellaSchool of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Jeffry Beta TenggaraDivision of Hematology and Medical Oncology, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.
Ralph Girson GunarsaGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.
Paulus SimadibrataGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.
Lianda SiregarGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.
Saut Horas Hatoguan NababanDivision of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Budiman Sujatmika SulaimanGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.
Irsan HasanGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.
Cosmas Rinaldi Adithya LesmanaGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.
Aru Wisaksono SudoyoGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy using immune checkpoint inhibitor (ICI) has been increasingly used in the oncology treatment field. Although ICIs could help suppress cancer and improve survival rates, it could also lead to certain adverse events, including immune-mediated liver injury caused by ICIs (ILICI). The manifestation of ILICI ranged greatly from asymptomatic disease to liver failure and even death. In this review article, we will discuss the pathogenesis, manifestation, and clinical approach of ILICI.

Identifiers

PMID41605828
PMCPMC12857653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.